Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)

Aditi Sharma, Joel Topf, Christiane A. Houde, Cathy Galasso, Sarah Phillips, Carmen Mitteer, Amanda Guido, Lori McFadden, Katelyn Staub, Amy Blake, Joseph Ellul, Andrew Kin, Craig Emmitt Cole, Abhinav Deol, Joseph Schiavi, Seongho Kim, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 1927.2.

https://doi.org/10.1182/blood-2024-211533

Published: 2024

Journal Articles

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Patrick Hagen, Surbhi Sidana, Terri L. Parker, Brian A. Walker, Vaishali Sanchorawala, Jeffrey A. Zonder, Taxiarchis Kourelis, Anita D'Souza, Heather J. Landau, Adam Rosenthal, Antje Hoering, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3309.1.

https://doi.org/10.1182/blood-2024-208227

Published: 2024

Journal Articles

Underrepresentation and Underreporting of Race/Ethnicity in Systemic Light Chain Amyloidosis NCCN Guidelines

Katrina Reid, Nikhil Vojjala, Hajir Alobaidi, Christiane A. Houde, Danielle Ross, Stephen Caucci, Jeffrey A. Zonder, Craig Emmitt Cole

Blood (2024) 144 (Supplement 1): 7600.

https://doi.org/10.1182/blood-2024-211922

Published: 2024

Journal Articles

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Dipenkumar Modi, Jay Yang, Seongho Kim, Asfar Azmi, Emily Tolksdorf, Christiane A. Houde, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 3123.4.

https://doi.org/10.1182/blood-2024-209059

Published: 2024

Journal Articles

Trial in Progress: Iberdomide and Daratumumab As Maintenance Therapy after an Autologous Stem Cell Transplant for Multiple Myeloma (the IBEX Trial)

Andrew Kin, Jeffrey A. Zonder, Craig Emmitt Cole, Abhinav Deol, Suresh Kumar Balasubramanian, Seongho Kim, Christiane A. Houde, Joseph Ellul, Amy Blake, Katelyn Staub, Amanda Guido, Erik Carr, Sarah Phillips, Julie Boerner

Blood (2024) 144 (Supplement 1): 7007.

https://doi.org/10.1182/blood-2024-210562

Published: 2024

Journal Articles

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Nadine Abdallah, Jay R. Hydren, Mason S. Barnes, Andrew Wood, Sascha Alexander Tuchman, Jeffrey A. Zonder, Giada Bianchi, Heather J. Landau, Muhamed Baljevic, James E. Hoffman, Ana M. Sahagun Sanchez Aldana, Jorge Arturo Hurtado Martinez, Jennifer M. Ahlstrom, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 5143.

https://doi.org/10.1182/blood-2024-208737

Published: 2024

Journal Articles

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Blood (2024) 144 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2024-206496

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Morie A. Gertz, Heather J. Landau, Vaishali Sanchorawala, Manisha Bhutani, Jeffrey A. Zonder, Michael Rosenzweig, Gray Magee, Cynthia Campos, Irina Yermilov, Eunice Chang, Michael S. Broder, Preeti Bajaj

Blood (2024) 144 (Supplement 1): 3665.

https://doi.org/10.1182/blood-2024-206132

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Journal Articles

Insufficient Representation and Reporting of Race in the References Forming the Basis of the National Comprehensive Cancer Network Guidelines for Multiple Myeloma

Danielle Ross, Stephen Caucci, Hajir Alobaidi, Christiane A. Houde, Katrina Reid, Nikhil Vojjala, Jeffrey A. Zonder, Craig Emmitt Cole

Blood (2024) 144 (Supplement 1): 2285.

https://doi.org/10.1182/blood-2024-211842

Published: 2024

Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2024-209952

Published: 2024

Journal Articles

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2024-210377

Published: 2024

Journal Articles

Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial

J Christine Ye, Philip Boonstra, Erica L. Campagnaro, Matthew Pianko, Andrew Kin, Larry D Anderson, Jr., Brea Lipe, Moshe Talpaz, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2024-209505

Published: 2024

Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2023-182410

Published: 2023

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2023-186241

Published: 2023

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

NARROW

A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Underrepresentation and Underreporting of Race/Ethnicity in Systemic Light Chain Amyloidosis NCCN Guidelines

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Trial in Progress: Iberdomide and Daratumumab As Maintenance Therapy after an Autologous Stem Cell Transplant for Multiple Myeloma (the IBEX Trial)

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Insufficient Representation and Reporting of Race in the References Forming the Basis of the National Comprehensive Cancer Network Guidelines for Multiple Myeloma

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only